IMARC Group, a leading market research company, has recently releases report titled “Inhaled Nitric Oxide Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global inhaled nitric oxide market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights
How big is the inhaled nitric oxide market?
The global inhaled nitric oxide market size reached US$ 877.0 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,361.1 Million by 2028, exhibiting a growth rate (CAGR) of 7.8% during 2023-2028.
What is inhaled nitric oxide?
Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator that skilled doctors supervise at tertiary neonatal intensive care units (NICUs). It aids in regulating vascular muscle tone and treating hypoxemic respiratory failure among newborn children by enhancing ventilation-perfusion mismatch and minimizing hypertension and elevated pulmonary vascular resistance. Inhaled nitric oxide also assists in decreasing the need for extracorporeal membrane oxygenation (ECMO) and improving oxygenation. Currently, iNO therapy is being increasingly used as a rescue agent for acute respiratory distress syndrome (ARDS) patients.
Request for a sample copy of this report: https://www.imarcgroup.com/inhaled-nitric-oxide-market/requestsample
What are the growth prospects and trends in the inhaled nitric oxide industry?
The rising prevalence of various respiratory and other subsequent diseases in newborns, including persistent pulmonary hypertension and neonatal hypoxic respiratory failure (HRF), is driving the inhaled nitric oxide market. Furthermore, the growing geriatric population, who are more prone to atherosclerosis, hypertension, peripheral artery disease, thrombosis, etc., is also augmenting the product demand. Moreover, iNO is gaining immense traction for the treatment of chronic obstructive pulmonary disease (COPD), ARDS, asthma, etc. Additionally, iNO therapy is also being used against coronavirus stains as it helps in improving ventilation/perfusion in patients with severe pneumonia. Besides this, the ongoing research and development (RD) activities in the healthcare industry are anticipated to bolster the market growth in the coming years.
What is included in market segmentation?
The report has segmented the market into the following categories:
Breakup by Application:
- Neonatal Respiratory Treatment
- Chronic Obstructive Pulmonary Disease (COPD)
- Acute Respiratory Distress Syndrome (ARDS)
- Others
Breakup by Region:
- North America (U.S. Canada)
- Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Others)
- Asia Pacific (China, India, Japan, South Korea, Indonesia, Australia, and Others)
- Latin America (Brazil, Mexico)
- Middle East Africa
Who are the key players operating in the industry?
The report covers the major market players including:
- Air Liquide S.A
- Bellerophon Therapeutics
- Beyond Air Inc.
- Linde plc
- Mallinckrodt plc
- Merck KGaA
- Novoteris LLC
- Nu-Med Plus
- VERO Biotech LLC.
Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email: [email protected]
Follow us on Twitter: @imarcglobal
